US clinical-stage biotech Nurix Therapeutics (Nasdaq: NRIX) announced that Sanofi (Euronext: SAN) has exclusively licensed an ...

NX-5948 assigned the nonproprietary name “bexobrutideg”U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström ...

NX-5948 assigned the nonproprietary name "bexobrutideg"U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemiaAchieved $7M in milestones and a $15M ...

Most recently we announced that Sanofi exercised its option to exclusively license an undisclosed Nurix program targeting a previously undruggable transcription factor that is a central regulator ...

Nurix received a $15 million license extension fee from Sanofi under its 2019 collaboration agreement, bringing the total amount received by Nurix to date to $105 million Nurix is eligible for an ...

Reports Q1 revenue $18.45M, consensus $13.03M. “Nurix had a strong first quarter marked by important collaboration and regulatory achievements ...

Nurix stock gains as SNY expands its partnership, licensing a research program targeting a previously untreatable transcription factor for autoimmune diseases.

Nurix Therapeutics NRIX shares rose 8.7% on Wednesday after the company announced that Sanofi SNY has in-licensed exclusive rights to an undisclosed Nurix program aimed at a previously ...

Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. On average, analysts expect Nurix Therapeutics to post $-3 EPS for the current fiscal year and ...

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,690 shares of the business’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $19.85 ...